What insurance policy changes affect CPT 96417?

There are 8 tracked policy changes affecting CPT 96417, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 96417?

Payers that have issued tracked updates for CPT 96417 include: Aetna.

How do I get notified when CPT 96417 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 96417. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for CPT 96417?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

96417 — An additional separate chemotherapy drug given through an IV line during the same treatment session.: Insurance Policy Changes

96417 Insurance Policy Changes

CPT 96417, in plain terms, covers An additional separate intravenous chemotherapy drug given after the first one during the same treatment session. CPT 96417 is referenced in 8 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 96417 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Medium impact

Blinatumomab (Blincyto) (CPB 0891, reviewed 2025-10-30)

Aetna·Effective Oct 30, 2025

Aetna has updated its Clinical Policy Bulletin 0891 for blinatumomab (Blincyto), a bispecific CD19-directed CD3 T-cell engager used to treat CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). The policy clarifies medical necessity criteria for commercial plans, specifying coverage for induction therapy with tyrosine kinase inhibitors, consolidation/maintenance therapy, and relapsed/refractory disease, while designating all other indications as experimental/investigational. This is a fresh policy update (1 day old) requiring immediate implementation.

96417 Insurance Policy Changes

Belantamab Mafodotin-blmf (Blenrep) (CPB 0981, reviewed 2026-02-06)

Azacitidine (CPB 0960, reviewed 2026-06-12)

Ciltacabtagene Autoleucel (Carvykti) (CPB 1007, reviewed 2026-03-13)

Brexucabtagene Autoleucel (Tecartus) (CPB 0980, reviewed 2026-03-13)

Carfilzomib (Kyprolis) (CPB 0845, reviewed 2026-03-02)

Caplacizumab-yhdp (Cablivi) (CPB 0949, reviewed 2025-12-03)

Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn (Rylaze) (CPB 0864, reviewed 2025-12-02)

Blinatumomab (Blincyto) (CPB 0891, reviewed 2025-10-30)